AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AVXS
- Previous Close: $59.38
- 50 Day Moving Average: $55.46
- 200 Day Moving Average: $49.71
- 52-Week Range: $18.12 - $72.72
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -16.67
- P/E Growth: -0.97
- Market Cap: $1.59B
- Outstanding Shares: 27,676,000
- Return on Equity: -46.72%
- Return on Assets: -43.63%
Companies Related to AveXis:
- Current Ratio: 15.21%
- Quick Ratio: 15.21%
What is AveXis' stock symbol?
AveXis trades on the NASDAQ under the ticker symbol "AVXS."
Where is AveXis' stock going? Where will AveXis' stock price be in 2017?
7 brokerages have issued 12-month target prices for AveXis' stock. Their predictions range from $47.00 to $100.00. On average, they anticipate AveXis' stock price to reach $73.87 in the next year.
When will AveXis announce their earnings?
AveXis is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.
What are analysts saying about AveXis stock?
Here are some recent quotes from research analysts about AveXis stock:
According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (2/14/2017)
- Chardan Capital analysts commented, "On 23 December 2016, partners Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS)), announced the US FDA approved Spinraza (nusinersen), a chronically-administered SMN2 antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA) types 1 to 3. As discussed in our 27 December 2016 note, on efficacy, Figure 1 of the Spinraza label shows that 23% of SMA type 1 patients taking Spinraza died compared to 43% of untreated patients. We compare this to the phase I trial of AAV-based gene therapy (GT) AVXS-101 (a one-time treatment) from AveXis (Buy), where no SMA type 1 patients so far have died. On safety, as discussed in our 17 January 2017 industry note, the Spinraza label states that 11% of patients developed a platelet level below the lower limit of normal, compared to 0% of patients under sham treatment. Furthermore, as covered in both our 23 January 2017 industry note and in today's accompanying industry note, "Spinraza FDA review confirms our concerns of antisense platelet class effects", both Anthem Healthcare (unrated) and the FDA have expressed concerns regarding the safety of Spinraza."He added, "Considering the above efficacy and safety issues for Spinraza relative to AVXS-101, we reiterate our AVXS Buy rating, make AVXS a Chardan top pick for 2017, and increase our AVXS PT from $85 to $100 (+18%). We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch." (1/26/2017)
Who owns AveXis stock?
AveXis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Deerfield Management Co. (8.08%), RA Capital Management, LLC (6.80%), Franklin Resources Inc. (4.32%), Boxer Capital LLC (3.72%) and RTW Investments LP (3.07%). Company insiders that own AveXis stock include Bong Y Koh, James E Flynn and Paul B Manning.
Who sold AveXis stock? Who is selling AveXis stock?
AveXis' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Janus Capital Management LLC and Renaissance Technologies LLC.
Who bought AveXis stock? Who is buying AveXis stock?
AveXis' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, Franklin Resources Inc., RTW Investments LP, Russell Investments Group Ltd. and Pacad Investment Ltd.. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn.
How do I buy AveXis stock?
Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AveXis stock cost?
One share of AveXis stock can currently be purchased for approximately $57.51.